Trial Profile
Retrospective chart review of use of Dabrafenib plus Trametinib in the treatment of V600 BRAF-mutated metastatic melanoma patients
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 16 Jun 2021
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Acronyms DESCRIBE II
- 28 Jan 2016 New trial record